SCHEMBL8051665

SCHEMBL8051665

Cn1c(=O)c2c(Nc3ccccc3)n(Cc3ccc(-n4cncn4)cc3)nc2n(CC2CC2)c1=O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE1B Q01064 3/20 0.65
PDE2A O00408 3/20 0.59
PDE4D Q08499 2/20 0.59
PDE1A P54750 1/20 0.53
PDE1C Q14123 1/20 0.53
DPP4 P27487 1/20 0.39
PDE4A P27815 7/20 0.37
PDE5A O76074 3/20 0.37
PDE8A O60658 2/20 0.37
PDE3B Q13370 2/20 0.37
PDE11A Q9HCR9 2/20 0.37
PDE7B Q9NP56 2/20 0.37
PDE10A Q9Y233 2/20 0.37
ADORA3 P0DMS8 1/20 0.36
ADORA2A P29274 1/20 0.36
ADORA2B P29275 1/20 0.36
ADORA1 P30542 1/20 0.36
PDE9A O76083 1/20 0.35
PDE4B Q07343 1/20 0.35
PDE4C Q08493 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10201414 0.88 PDE1B (0.65) PDE1BPDE2APDE4DPDE1APDE1C
SCHEMBL2120812 0.88 PDE1B (0.50) PDE1BPDE2APDE4DPDE1APDE1C
SCHEMBL3011746 0.88 PDE1B (0.64) PDE1BPDE2APDE4DPDE1APDE1C
SCHEMBL2122099 0.80 PDE1B (0.42) PDE1BPDE2APDE4DPDE1APDE1C
SCHEMBL2119987 0.80 PDE1B (0.42) PDE1BPDE2APDE4DPDE1APDE1C
SCHEMBL20841529 0.77 PDE4A (0.45) PDE2APDE4APDE5APDE8APDE3B
SCHEMBL3010414 0.75 PDE1B (0.65) PDE1BPDE2APDE4DPDE1APDE1C
SCHEMBL2535845 0.74 PDE1B (0.49) PDE1BPDE2APDE1APDE1CDPP4
SCHEMBL8045647 0.73 PDE1B (0.64) PDE1BPDE2APDE4DPDE1APDE1C
SCHEMBL2537381 0.73 PDE1B (0.45) PDE1BPDE2APDE1APDE1CDPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10010553-B2 Organic compounds INTRA-CELLULAR THERAPIES, INC. (US) 2018-07-03 US disclosed
US-20150197524-A1 ORGANIC COMPOUNDS LI PENG (US) 2015-07-16 US disclosed
US-20150197524-A1 ORGANIC COMPOUNDS LI PENG (US) 2015-07-16 US disclosed
US-8846693-B2 Optionally substituted pyrazolo[3,4-d]pyrimidine-4,6-diones INTRA-CELLULAR THERAPIES, INC. (US) 2014-09-30 US disclosed
WO-2009073210-A1 ORGANIC COMPOUNDS INTRA-CELLULAR THERAPIES, INC (US) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150197524-A1 ORGANIC COMPOUNDS OPRD1, HTR1D, DRD1 PDE1B 115/4885PDE2A 83/4885PDE4D 89/4885
US-10010553-B2 Organic compounds PDE5A, PDE4A, PDE3A PDE1B 27/4885PDE2A 4/4885PDE4D 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.